Quick Links
Past Events

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Juno Therapeutics.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASH: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh In on Recent Data and Clinical Experience

ASH: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh In on Recent Data and Clinical Experience

December 8, 2017
Lunch and registration: 12:30 PM – 1:30 PM

Georgia World Congress Center
Lunch: B302-B305
Meeting Room: B308-B309
285 Andrew Young International Blvd NW
Atlanta, GA 30313

Registration is complimentary, but seating is limited.


Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh In on Recent Data and Clinical Experience is a live symposium to be held adjunct to the annual meeting in Atlanta. Outcomes for patients with lymphoid malignancies have improved dramatically over the past several decades as a result of personalization of care and the use of targeted agents in multiple lines of therapy. However, important unmet clinical needs remain, particularly for patients with relapsed/refractory disease.

Chimeric antigen receptor (CAR) T cells have recently emerged as a novel therapeutic approach, yielding complete responses even in heavily pretreated patients with leukemia, lymphoma, and myeloma; they also are being explored in solid tumors. However, CAR T cells represent a major paradigm shift from conventional management strategies, and there is a clear educational need to address knowledge and competence gaps among physicians regarding clinical data with CAR T cells, key considerations in the administration of these agents, and methods to manage the unique spectrum of treatment-related adverse events associated with these therapies.

To address these educational gaps, this symposium will feature internationally renowned experts in CAR T-cell therapy who will discuss the science and clinical data underlying these new therapeutic approaches, as well as practical advice for incorporating CAR T cells in treatment algorithms for patients with lymphoid malignancies. Extended question-and-answer sessions will also provide opportunities for interaction between the expert faculty and participants.

Key topics to be addressed by faculty include:

  • The scientific principles underlying the use of CAR T cells in cancer therapy
  • Current applications of CAR T-cell therapy in lymphoid malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia
  • Emerging approaches to improving the delivery of CAR T cells
  • Proactive methods to mitigate and manage adverse events associated with CAR T-cell therapies

The symposium will be held at the Georgia World Congress Center, on December 8, 2017, from 12:30 PM to 4:30 PM. Please join us in Atlanta to learn about the latest developments in CAR T-cell therapy in hematologic malignancies. This is a symposium not to be missed!

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the structure and function of the CAR and the mechanism of action of CAR T cells in lymphoma
  • Review clinical trial evidence, with a focus on non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, and describe where CAR T-cell therapies might fit in the treatment landscape
  • Review clinical trial evidence in other lymphoid malignancies and describe where CAR T-cell therapy might fit in that treatment landscape
  • Identify and discuss the management of toxicities of CAR T-cell therapies

Activity Chair

David Maloney, MD, PhD
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
Seattle, WA

Become a Member

Forgot Password?
Calendar of Events
Filter By